The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of perioperative chemotherapy of esophageal cancer: PIECE trial.
 
Motoo Nomura
No Relationships to Disclose
 
Masahiro Goto
Honoraria - DAIICHI SANKYO COMPANY,LIMITED; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Sumitomo Dainippon Pharma Co., Ltd.; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Chugai Pharma; Nippon Kayaku; Taiho Pharmaceutical
 
Masayuki Watanabe
No Relationships to Disclose
 
Shinji Hato
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Eishi Baba
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck; Miyarisan pharmaceutical; MSD; Sanofi; Sanofi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Hisahiro Matsubara
No Relationships to Disclose
 
Hidenori Mukaida
No Relationships to Disclose
 
Takako Yoshii
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; Ethicon; Kaken Pharmaceutical; MSD K.K.; Nippon Covidien; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)
 
Ishikawa Hideki
No Relationships to Disclose
 
Manabu Muto
No Relationships to Disclose